SBIR/STTR Research Award

DEVELOPMENT OF NUCLEAR RECEPTORS AS ANTHELMINTIC TARGETS

Award identifier 9ef8267164a8dc5fa7713a06037c3587ac16f32a65965e788cc6995a68ff6625Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$746,396

Program and phase

SBIR · Phase II

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CAMBRIA BIOSCIENCES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by applicant): Over one billion people worldwide are infected by parasitic nematodes that cause various debilitating nutritional, gastrointestinal, and other diseases. Many such infections are not curable with existing medications, and preventive vaccines are not yet feasible for these complex parasites. The long-term goal of this project is to identify new anti-nematode compounds that will fulfill this human health need. Nuclear receptor (NR) transcription factors are proven targets of effective and commercially successful drugs and insecticides, but have not yet been exploited as anthelmintic targets. Compounds that selectively interfere with the functions of NRs essential for nematode viability will provide leads for the development of novel anthelmintics for the control of important human parasitic nematode infections. The results of Phase I identified parasitic nematode orthologs of NRs that have essential functions in C. elegans and established a cell-based assay for chemical modulators of nematode NR activity. Phase II will exploit the knowledge and tools acquired during Phase I to deploy a proprietary battery of high-throughput screens for isolating compounds that alter nematode NR function. Secondary assays will be used to select those active compounds that are most promising for further development in Phase III. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.